1
|
Duncan M, Bansal D, Cooke E. Help-seeking intentions of UK construction workers: a cross-sectional study. Occup Med (Lond) 2024; 74:172-177. [PMID: 38319790 PMCID: PMC10990463 DOI: 10.1093/occmed/kqae007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2024] Open
Abstract
BACKGROUND In response to the high rates of poor mental health in the construction industry, numerous workplace interventions have been designed to address the known and suspected risk factors to employee mental health and well-being. A key challenge of these strategies is low engagement in support services. AIMS The goals of this research were to investigate the help-seeking intentions of employees in the construction industry, explore levels of mental well-being in this population and provide insight into employee engagement with mental health support strategies. METHODS Employees from two UK construction companies completed an online cross-sectional questionnaire (n = 119), designed to measure help-seeking intentions, levels of mental well-being and worker attitudes towards workplace mental health support strategies. RESULTS One-third of the sample reported experiencing an episode of mental health difficulties in the past 6 months. Employees reported a greater preference for seeking support from informal versus formal help sources. Participants were most likely to seek help from a partner and least likely to seek help from a Mental Health First Aider/ Champion. The study also showed some association between help-seeking intention and age of employees. CONCLUSIONS Given the poor levels of mental well-being in this population, it is essential that adequate workplace support is provided. Whilst formal help sources are important for this population, our study highlights the potential benefits of informal help sources to support employees. Future interventions may therefore wish to consider developing tailored, informal workplace support networks and programmes.
Collapse
Affiliation(s)
- M Duncan
- Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London SE1 1UL, UK
| | - D Bansal
- Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London SE1 1UL, UK
| | | |
Collapse
|
2
|
Ehmann F, Kuhn A, Pasmooij AMG, Humphreys A, Van Hengel A, Dooley B, Anliker B, Svensson C, Capaldi D, Henshall D, Cooke E, Zhou H, Bastaerts H, Smink J, Van Gerven J, Enes L, Nechev L, Hoefnagel M, Driessens M, Wenger M, Blanquie O, Widomski P, Herold R, Thürmer R, Ruiz S, Thirstrup S, Goody S, Zaks T, Cordò V, Aartsma-Rus AM. Report of the European Medicines Agency Conference on RNA-Based Medicines. Nucleic Acid Ther 2024; 34:4-11. [PMID: 38174996 DOI: 10.1089/nat.2023.0021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2024] Open
Abstract
RNA-based medicines have potential to treat a large variety of diseases, and research in the field is very dynamic. Proactively, The European Medicines Agency (EMA) organized a virtual conference on February 2, 2023 to promote the development of RNA-based medicines. The initiative addresses the goal of the EMA Regulatory Science Strategy to 2025 to "catalyse the integration of science and technology in medicines development." The conference focused on RNA technologies (excluding RNA vaccines) and involved different stakeholders, including representatives from academia, industry, regulatory authorities, and patient organizations. The conference comprised presentations and discussion sessions conducted by panels of subject matter experts. In this meeting report, we summarize the presentations and recap the main themes of the panel discussions.
Collapse
Affiliation(s)
- Falk Ehmann
- European Medicines Agency, Amsterdam, The Netherlands
| | | | | | | | - Arjon Van Hengel
- DG Research and Innovation, European Commission, Brussels, Belgium
| | - Brian Dooley
- European Medicines Agency, Amsterdam, The Netherlands
| | | | | | | | - David Henshall
- RCSI University of Medicine and Health Sciences College of Surgeons RCSI and FutureNeuro SFI Research Centre, Dublin, Ireland
| | - Emer Cooke
- European Medicines Agency, Amsterdam, The Netherlands
| | - Haiyan Zhou
- University College London (UCL), NIHR Great Ormond Street Hospital Biomedical Research Centre, London, United Kingdom
| | | | | | - Joop Van Gerven
- Central Committee on Research Involving Human Subjects (CCMO), The Hague, The Netherlands
| | - Leonor Enes
- European Medicines Agency, Amsterdam, The Netherlands
| | - Lubomir Nechev
- Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts, USA
| | | | - Mariëtte Driessens
- VSOP - Patient Alliance for Rare and Genetic Diseases, Soest, The Netherlands
| | | | - Oriane Blanquie
- European Medicines Agency, Amsterdam, The Netherlands
- Department of Dermatology, University Medical Center of the Johannes Gutenberg-University Mainz, Germany
| | | | - Ralf Herold
- European Medicines Agency, Amsterdam, The Netherlands
| | - René Thürmer
- Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany
| | - Sol Ruiz
- Agency of Medicines and Medical Products (AEMPS), Madrid, Spain
| | | | | | - Tal Zaks
- OrbiMed, Boston, Massachusetts, USA
| | | | | |
Collapse
|
3
|
Cernuschi T, Malvolti S, Hall S, Debruyne L, Bak Pedersen H, Rees H, Cooke E. The quest for more effective vaccine markets - Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic. Vaccine 2022:S0264-410X(22)00920-3. [PMID: 38103962 PMCID: PMC9585501 DOI: 10.1016/j.vaccine.2022.07.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2021] [Revised: 03/28/2022] [Accepted: 07/22/2022] [Indexed: 11/13/2022]
Abstract
The past two decades have seen important progress in access to timely, reliable, affordable, and quality-assured supplies of vaccines of global public health importance. The new vaccines developed are powerful tools to fight killers such as pneumonia, diarrhea, and cervical cancer. Global and regional financing and pooled procurement haveshortened the lag between access in high- andlower-income countries. The COVID-19 pandemic has shown that by addressing shortcomings and seizing opportunities, we can do even more. In response to COVID-19, vaccine development and access shifted from a sequential, risk-averse paradigm to a rapid approach with maximum compression of time to market while ensuring quality. Vast public investments and innovative technologies were key facilitators. The pandemic has shown that governments play a crucial role in investing in new vaccines and manufacturing capacity and sharing risks with industry. Despite impressive progress, equity in access remains elusive with important moral, economic, and health-related consequences. Global leaders are working on a new International Treaty for Pandemic Prevention, Preparedness, and Response. To apply the lessons of COVID-19, that treaty should include a new paradigm for access to vaccines in which governments agree to:This would ensure that COVID-19 catalyzes a shift toward greater access for all under Immunization Agenda 2030.
Collapse
Affiliation(s)
- Tania Cernuschi
- Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
| | | | - Shanelle Hall
- The Yellow House, Seattle, WA, USA; The Yellow House, Copenhagen, Denmark
| | - Luc Debruyne
- Access-to-Medicines Research Center, KU Leuven, Leuven, Belgium
| | | | - Helen Rees
- Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa; Chairperson of the South African Health Products Regulatory Authority Board, South Africa
| | - Emer Cooke
- European Medicines Agency, Amsterdam, North Holland, Netherlands
| |
Collapse
|
4
|
Cooke E. Preparing Europe for future health threats and crises ─ the European Medicines Agency; ensuring safe and effective medicines and medical devices. Euro Surveill 2022; 27. [PMID: 36268739 PMCID: PMC9585881 DOI: 10.2807/1560-7917.es.2022.27.42.2200798] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- Emer Cooke
- European Medicines Agency (EMA), Amsterdam, the Netherlands
| |
Collapse
|
5
|
Klimek L, Agache I, Cooke E, Jutel M, Akdis CA, O'Hehir R. COVID-19 vaccines-The way forward. Allergy 2022; 77:15-16. [PMID: 34191300 PMCID: PMC8441906 DOI: 10.1111/all.14995] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2021] [Revised: 06/08/2021] [Accepted: 06/19/2021] [Indexed: 01/17/2023]
Affiliation(s)
- Ludger Klimek
- Center for Rhinology and Allergology Wiesbaden Germany
| | - Ioana Agache
- Faculty of Medicine Transylvania University Brasov Romania
| | - Emer Cooke
- European Medicines Agency Amsterdam Netherlands
| | - Marek Jutel
- Department of Clinical Immunology Wroclaw Medical University Wroclaw Poland
- All‐MED Medical Research Institute Wroclaw Poland
| | - Cezmi A. Akdis
- Swiss Institute of Allergy and Asthma Research (SIAF) University of Zurich Davos Switzerland
| | - Robyn O'Hehir
- Department of Immunology and Pathology Monash University Melbourne Vic. Australia
- Department of Allergy, Immunology and Respiratory Medicine Central Clinical School Monash Vic. Australia
| |
Collapse
|
6
|
Arlett P, Kjaer J, Broich K, Cooke E. Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value. Clin Pharmacol Ther 2021; 111:21-23. [PMID: 34797920 PMCID: PMC9299492 DOI: 10.1002/cpt.2479] [Citation(s) in RCA: 72] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2021] [Accepted: 11/01/2021] [Indexed: 11/09/2022]
Affiliation(s)
- Peter Arlett
- European Medicines Agency, Amsterdam, Netherlands
| | | | | | - Emer Cooke
- European Medicines Agency, Amsterdam, Netherlands
| |
Collapse
|
7
|
Abou-el-Enein M, Angelis A, Appelbaum FR, Andrews NC, Bates SE, Bierman AS, Brenner MK, Cavazzana M, Caligiuri MA, Clevers H, Cooke E, Daley GQ, Dzau VJ, Ellis LM, Fineberg HV, Goldstein LS, Gottschalk S, Hamburg MA, Ingber DE, Kohn DB, Krainer AR, Maus MV, Marks P, Mummery CL, Pettigrew RI, Rutter JL, Teichmann SA, Terzic A, Urnov FD, Williams DA, Wolchok JD, Lawler M, Turtle CJ, Bauer G, Ioannidis JP. Evidence generation and reproducibility in cell and gene therapy research: A call to action. Mol Ther Methods Clin Dev 2021; 22:11-14. [PMID: 34377737 PMCID: PMC8322039 DOI: 10.1016/j.omtm.2021.06.012] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Affiliation(s)
- Mohamed Abou-el-Enein
- Division of Medical Oncology, Department of Medicine and Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
- Joint USC/CHLA Cell Therapy Program, University of Southern California and Children’s Hospital Los Angeles, Los Angeles, CA, USA
| | - Aris Angelis
- Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK
- Department of Health Policy and LSE Health, London School of Economics and Political Science, London, UK
| | - Frederick R. Appelbaum
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA
| | - Nancy C. Andrews
- Department of Pharmacology and Cancer Biology and Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA
| | - Susan E. Bates
- Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NY, USA
| | - Arlene S. Bierman
- Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, Rockville, MD, USA
| | - Malcolm K. Brenner
- Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA
| | - Marina Cavazzana
- Biotherapy Department, Necker Children’s Hospital, Assistance Publique-Hopitaux de Paris, Paris, France
- Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Quest, INSERM, Paris, France
| | - Michael A. Caligiuri
- Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope National Medical Center, Duarte, CA, USA
| | - Hans Clevers
- Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), Utrecht, the Netherlands
- University Medical Center Utrecht, Utrecht, the Netherlands
| | - Emer Cooke
- European Medicines Agency, Amsterdam, the Netherlands
| | - George Q. Daley
- Boston Children’s Hospital, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
| | | | - Lee M. Ellis
- Department of Surgical Oncology and Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | | | - Lawrence S.B. Goldstein
- Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA
- Sanford Consortium for Regenerative Medicine, La Jolla, CA, USA
| | - Stephen Gottschalk
- Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital, Memphis, TN, USA
| | - Margaret A. Hamburg
- American Association for the Advancement of Science (AAAS), Washington, DC, USA
- National Academy of Medicine, Washington, DC, USA
| | - Donald E. Ingber
- Boston Children’s Hospital, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA
- Harvard John A. Paulson School of Engineering and Applied Sciences, Cambridge, MA, USA
| | - Donald B. Kohn
- Department of Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
- The Eli & Edith Broad Center of Regenerative Medicine & Stem Cell Research, University of California, Los Angeles, Los Angeles, CA, USA
| | | | - Marcela V. Maus
- Harvard Medical School, Boston, MA, USA
- Massachusetts General Hospital Cancer Center, Charlestown, MA, USA
| | - Peter Marks
- Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
| | - Christine L. Mummery
- Department of Anatomy and Embryology, Leiden University Medical Center, Leiden, the Netherlands
| | - Roderic I. Pettigrew
- ENMED, Colleges of Medicine and Engineering, Texas A&M University, Houston, TX, USA
| | - Joni L. Rutter
- National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA
| | - Sarah A. Teichmann
- Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK
- Theory of Condensed Matter, Cavendish Laboratory, University of Cambridge, JJ Thomson Ave, Cambridge, UK
| | - Andre Terzic
- Center for Regenerative Medicine, Mayo Clinic, Rochester, MN, USA
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA
| | - Fyodor D. Urnov
- Innovative Genomics Institute, University of California, Berkeley, CA, USA
| | - David A. Williams
- Boston Children’s Hospital, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- Division of Hematology/Oncology, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, MA, USA
| | - Jedd D. Wolchok
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA
| | - Mark Lawler
- Patrick G Johnston Centre for Cancer Research, Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast, Belfast, UK
| | - Cameron J. Turtle
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA
| | - Gerhard Bauer
- Institute for Regenerative Cures, University of California, Davis, Sacramento, CA, USA
| | - John P.A. Ioannidis
- Stanford Prevention Research Center, Department of Medicine, Stanford University, Stanford, CA, USA
- Department of Epidemiology and Population Health and Department of Biomedical Data Sciences, Stanford University, Stanford, CA, USA
| |
Collapse
|
8
|
Wilson JL, Cheung KWK, Lin L, Green EAE, Porrás AI, Zou L, Mukanga D, Akpa PA, Darko DM, Yuan R, Ding S, Johnson WCN, Lee HA, Cooke E, Peck CC, Kern SE, Hartman D, Hayashi Y, Marks PW, Altman RB, Lumpkin MM, Giacomini KM, Blaschke TF. Scientific considerations for global drug development. Sci Transl Med 2021; 12:12/554/eaax2550. [PMID: 32727913 DOI: 10.1126/scitranslmed.aax2550] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2019] [Revised: 06/05/2019] [Accepted: 11/05/2019] [Indexed: 12/12/2022]
Abstract
Requiring regional or in-country confirmatory clinical trials before approval of drugs already approved elsewhere delays access to medicines in low- and middle-income countries and raises drug costs. Here, we discuss the scientific and technological advances that may reduce the need for in-country or in-region clinical trials for drugs approved in other countries and limitations of these advances that could necessitate in-region clinical studies.
Collapse
Affiliation(s)
- Jennifer L Wilson
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA
| | - Kit Wun Kathy Cheung
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA
| | - Lawrence Lin
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA
| | - Elizabeth A E Green
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA
| | - Analia I Porrás
- Medicines and Health Technologies Unit, Department of Health Systems and Services, Pan American Health Organization, Regional Office of the World Health Organization, Washington, DC, USA
| | - Ling Zou
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA
| | - David Mukanga
- Global Health, Bill and Melinda Gates Foundation, Seattle, WA, USA
| | - Paul A Akpa
- Department of Pharmaceutics, University of Nigeria, Nsukka, Enugu State, Nigeria
| | | | - Rae Yuan
- Sinovant Sciences Co., Shanghai, China
| | - Sheng Ding
- School of Pharmaceutical Sciences, Tsinghua University, Beijing, China.,Gladstone Institute of Cardiovascular Disease, San Francisco, CA, USA
| | | | - Howard A Lee
- Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.,Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Suwon, Republic of Korea
| | - Emer Cooke
- World Health Organization, Geneva, Switzerland
| | - Carl C Peck
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.,NDA Partners LLC, San Luis Obispo, CA, USA
| | - Steven E Kern
- Global Health, Bill and Melinda Gates Foundation, Seattle, WA, USA
| | - Dan Hartman
- Global Health, Bill and Melinda Gates Foundation, Seattle, WA, USA
| | | | - Peter W Marks
- Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA
| | - Russ B Altman
- Departments of Bioengineering and Genetics, Stanford University, Stanford, CA, USA
| | - Murray M Lumpkin
- Global Health, Bill and Melinda Gates Foundation, Seattle, WA, USA
| | - Kathleen M Giacomini
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.
| | - Terrence F Blaschke
- Departments of Medicine and Molecular Pharmacology, Stanford University School of Medicine, Stanford, CA, USA
| |
Collapse
|
9
|
Affiliation(s)
- Marco Cavaleri
- European Medicines Agency, 1083 HS Amsterdam, Netherlands.
| | - Harald Enzmann
- European Medicines Agency, 1083 HS Amsterdam, Netherlands; Federal Institute for Drugs and Medical Devices, European Union and International Affairs, Bonn, Germany
| | - Sabine Straus
- European Medicines Agency, 1083 HS Amsterdam, Netherlands; Medicines Evaluation Board, Utrecht, Netherlands
| | - Emer Cooke
- European Medicines Agency, 1083 HS Amsterdam, Netherlands
| |
Collapse
|
10
|
Ndomondo-Sigonda M, Mahlangu G, Agama-Anyetei M, Cooke E. A new approach to an old problem: Overview of the East African Community's Medicines Regulatory Harmonization initiative. PLoS Med 2020; 17:e1003099. [PMID: 32785223 PMCID: PMC7423057 DOI: 10.1371/journal.pmed.1003099] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Affiliation(s)
| | | | | | - Emer Cooke
- World Health Organization, Geneva, Switzerland
| |
Collapse
|
11
|
Arik M, Bamenyekanye E, Fimbo A, Kabatende J, Kijo AS, Simai B, Siyoi F, Azatyan S, Ambali A, Cooke E, Mashingia JH, Mwesigye JP, Ndomondo-Sigonda M, Sillo H, Sonoiya S, Tanui P, Ward M, Delano T. Optimizing the East African Community's Medicines Regulatory Harmonization initiative in 2020-2022: A Roadmap for the Future. PLoS Med 2020; 17:e1003129. [PMID: 32785229 PMCID: PMC7423061 DOI: 10.1371/journal.pmed.1003129] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Margareth Ndomondo-Sigonda outlines future challenges for the East African Medicines Regulatory Harmonization initiative.
Collapse
Affiliation(s)
- Mawien Arik
- Drug and Food Control Authority, Juba, South Sudan
| | | | - Adam Fimbo
- Tanzania Medicines and Medical Devices Authority, Dar Es Salaam, Tanzania
| | | | - Agnes Sitta Kijo
- Tanzania Medicines and Medical Devices Authority, Dar Es Salaam, Tanzania
| | - Burhani Simai
- Zanzibar Food and Drug Agency, Zanzibar City, Zanzibar
| | - Fred Siyoi
- Pharmacy and Poisons Board, Nairobi, Kenya
| | | | - Aggrey Ambali
- African Union Development Agency–New Partnership for Africa’s Development, Midrand, South Africa
| | - Emer Cooke
- World Health Organization, Geneva, Switzerland
| | | | | | - Margareth Ndomondo-Sigonda
- African Union Development Agency–New Partnership for Africa’s Development, Midrand, South Africa
- * E-mail:
| | - Hiiti Sillo
- World Health Organization, Geneva, Switzerland
| | | | - Paul Tanui
- African Union Development Agency–New Partnership for Africa’s Development, Midrand, South Africa
| | - Mike Ward
- World Health Organization, Geneva, Switzerland
| | | |
Collapse
|
12
|
Affiliation(s)
- Tippi K Mak
- Centre of Regulatory Excellence, Duke-NUS Medical School, Singapore
- SingHealth Duke-NUS Global Health Institute, Singapore
- Vaccine and Infectious Disease Organization-International Vaccine Centre, University of Saskatchewan, Canada
| | - John Cw Lim
- Centre of Regulatory Excellence, Duke-NUS Medical School, Singapore
- SingHealth Duke-NUS Global Health Institute, Singapore
| | | | | | - Emer Cooke
- Access to Medicines and Health Products Division, World Health Organization, Geneva, Switzerland
| | | |
Collapse
|
13
|
Oakes C, Staton S, Houen S, Cooke E, Pattinson C, Teo SL, Thorpe K. “Did my child sleep today?”: communication between parents and educators in childcare settings. Sleep Med 2019. [DOI: 10.1016/j.sleep.2019.11.1070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
14
|
Staton S, Rankin P, Thorpe K, Oakes C, Houen S, Cooke E, Smith S. Improving sleep health in early childhood: pilot rct of an educator professional development program to improve sleep practices in childcare services. Sleep Med 2019. [DOI: 10.1016/j.sleep.2019.11.1013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
15
|
Minghui R, Malecela MN, Cooke E, Abela-Ridder B. WHO's Snakebite Envenoming Strategy for prevention and control. Lancet Glob Health 2019; 7:e837-e838. [PMID: 31129124 DOI: 10.1016/s2214-109x(19)30225-6] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/08/2019] [Accepted: 05/10/2019] [Indexed: 10/26/2022]
|
16
|
Roth L, Bempong D, Babigumira JB, Banoo S, Cooke E, Jeffreys D, Kasonde L, Leufkens HGM, Lim JCW, Lumpkin M, Mahlangu G, Peeling RW, Rees H, Ndomondo-Sigonda M, Stergachis A, Ward M, Nwokike J. Expanding global access to essential medicines: investment priorities for sustainably strengthening medical product regulatory systems. Global Health 2018; 14:102. [PMID: 30382856 PMCID: PMC6211488 DOI: 10.1186/s12992-018-0421-2] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2018] [Accepted: 10/10/2018] [Indexed: 01/08/2023] Open
Abstract
Access to quality-assured medical products improves health and save lives. However, one third of the world's population lacks timely access to quality-assured medicines while estimates indicate that at least 10% of medicine in low- and middle-income countries (LMICs) are substandard or falsified (SF), costing approximately US$ 31 billion annually. National regulatory authorities are the key government institutions that promote access to quality-assured medicines and combat SF medical products but despite progress, regulatory capacity in LMICs is still insufficient. Continued and increased investment in regulatory system strengthening (RSS) is needed. We have therefore reviewed existing global normative documents and resources and engaged with our networks of global partners and stakeholders to identify three critical challenges being faced by NRAs in LMICs that are limiting access to medical products and impeding detection of and response to SF medicines. The challenges are; implementing value-added regulatory practices that best utilize available resources, a lack of timely access to new, quality medical products, and limited evidence-based data to support post-marketing regulatory actions. To address these challenges, we have identified seven focused strategies; advancing and leveraging convergence and reliance initiatives, institutionalizing sustainability, utilizing risk-based approaches for resource allocation, strengthening registration efficiency and timeliness, strengthening inspection capacity and effectiveness, developing and implementing risk-based post-marketing quality surveillance systems, and strengthening regulatory management of manufacturing variations. These proposed solutions are underpinned by 13 focused recommendations, which we believe, if financed, technically supported and implemented, will lead to stronger health system and as a consequence, positive health outcomes.
Collapse
Affiliation(s)
- Lukas Roth
- United States Pharmacopeia, Rockville, USA
| | | | - Joseph B. Babigumira
- Global Medicines Program, School of Pharmacy, School of Public Health, University of Washington, Seattle, USA
| | - Shabir Banoo
- Right to Care, South African Health Products Regulatory Authority, Cape Town, South Africa
| | - Emer Cooke
- World Health Organization, Geneva, Switzerland
| | - David Jeffreys
- International Federation of Pharmaceutical Manufacturers and Associations Regulatory Science Committee, Geneva, Switzerland
| | | | - Hubert G. M. Leufkens
- Division of Pharmacoepidemiology and Clinical Pharmacology, University of Utrecht, Utrecht, Netherlands
| | - John C. W. Lim
- Centre of Regulatory Excellence, Duke-National University of Singapore Medical School, Singapore, Singapore
| | | | - Gugu Mahlangu
- Medicines Control Authority Zimbabwe, Harare, Zimbabwe
| | | | - Helen Rees
- South African Health Products Regulatory Authority, University of Witwatersand, Johannesburg, South Africa
| | | | - Andy Stergachis
- Global Medicines Program, School of Pharmacy, School of Public Health, University of Washington, Seattle, USA
| | - Mike Ward
- World Health Organization, Geneva, Switzerland
| | - Jude Nwokike
- Promoting the Quality of Medicines program, United States Pharmacopeia, Rockville, USA
| |
Collapse
|
17
|
Beattie WS, Wijeysundera DN, Chan MTV, Peyton PJ, Leslie K, Paech MJ, Sessler DI, Wallace S, Myles PS, Galagher W, Farrington C, Ditoro A, Baulch S, Sidiropoulos S, Bulach R, Bryant D, O’Loughlin E, Mitteregger V, Bolsin S, Osborne C, McRae R, Backstrom M, Cotter R, March S, Silbert B, Said S, Halliwell R, Cope J, Fahlbusch D, Crump D, Thompson G, Jefferies A, Reeves M, Buckley N, Tidy T, Schricker T, Lattermann R, Iannuzzi D, Carroll J, Jacka M, Bryden C, Badner N, Tsang MWY, Cheng BCP, Fong ACM, Chu LCY, Koo EGY, Mohd N, Ming LE, Campbell D, McAllister D, Walker S, Olliff S, Kennedy R, Eldawlatly A, Alzahrani T, Chua N, Sneyd R, McMillan H, Parkinson I, Brennan A, Balaji P, Nightingale J, Kunst G, Dickinson M, Subramaniam B, Banner-Godspeed V, Liu J, Kurz A, Hesler B, Fu AY, Egan C, Fiffick AN, Hutcherson MT, Turan A, Naylor A, Obal D, Cooke E. Implication of Major Adverse Postoperative Events and Myocardial Injury on Disability and Survival. Anesth Analg 2018. [DOI: 10.1213/ane.0000000000003310] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
18
|
Kendrick T, Marchant J, Tsang N, Nkazana K, McGeever J, Cooke E, Grant T. Humidified high flow therapy in paediatric patients referred for retrieval to the NSW newborn and paediatric emergency transport service (NETS). Aust Crit Care 2018. [DOI: 10.1016/j.aucc.2017.12.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
19
|
Brown ZE, Görges M, Cooke E, Malherbe S, Dumont GA, Ansermino JM. Changes in cardiac index and blood pressure on positioning children prone for scoliosis surgery. Anaesthesia 2013; 68:742-6. [PMID: 23710730 DOI: 10.1111/anae.12310] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/17/2013] [Indexed: 01/01/2023]
Abstract
In this prospective observational study we investigated the changes in cardiac index and mean arterial pressure in children when positioned prone for scoliosis correction surgery. Thirty children (ASA 1-2, aged 13-18 years) undergoing primary, idiopathic scoliosis repair were recruited. The cardiac index and mean arterial blood pressure (median (IQR [range])) were 2.7 (2.3-3.1 [1.4-3.7]) l.min(-1).m(-2) and 73 (66-80 [54-91]) mmHg, respectively, at baseline; 2.9 (2.5-3.2 [1.7-4.4]) l.min(-1).m(-2) and 73 (63-81 [51-96]) mmHg following a 5-ml.kg(-1) fluid bolus; and 2.5 (2.2-2.7 [1.4-4.8]) l.min(-1).m(-2) and 69 (62-73 [46-85]) mmHg immediately after turning prone. Turning prone resulted in a median reduction in cardiac index of 0.5 l.min(-1).m(-2) (95% CI 0.3-0.7 l.min(-1).m(-2), p=0.001), or 18.5%, with a large degree of inter-subject variability (+10.3% to -40.9%). The changes in mean arterial blood pressure were not significant. Strategies to predict, prevent and treat decreases in cardiac index need to be developed.
Collapse
Affiliation(s)
- Z E Brown
- Department of Anesthesiology, Pharmacology & Therapeutic, The University of British Columbia, Vancouver, British Columbia, Canada
| | | | | | | | | | | |
Collapse
|
20
|
Chandler JR, Cooke E, Petersen C, Karlen W, Froese N, Lim J, Ansermino JM. Pulse oximeter plethysmograph variation and its relationship to the arterial waveform in mechanically ventilated children. J Clin Monit Comput 2012; 26:145-51. [DOI: 10.1007/s10877-012-9347-z] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2011] [Accepted: 02/25/2012] [Indexed: 12/01/2022]
|
21
|
Howell WH, Cooke E. Action of the Inorganic Salts of Serum, Milk, Gastric Juice, etc., upon the isolated working Heart, with remarks upon the causation of the Heart-beat. J Physiol 2007; 14:198-220. [PMID: 16992043 PMCID: PMC1514369 DOI: 10.1113/jphysiol.1893.sp000447] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
|
22
|
|
23
|
Pomeroy VM, Cooke E, Hamilton S, Whittet A, Tallis RC. Development of a schedule of current physiotherapy treatment used to improve movement control and functional use of the lower limb after stroke: a precursor to a clinical trial. Neurorehabil Neural Repair 2006; 19:350-9. [PMID: 16263967 DOI: 10.1177/1545968305280581] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
OBJECTIVE To develop a treatment schedule of physical therapy techniques used to improve movement control and functional use of the paretic lower limb after stroke in U.K. clinical centers to be involved in a subsequent clinical trial of experimental interventions given in addition to routine clinical practice. METHODS Ten physiotherapists experienced in stroke rehabilitation who worked in or near the clinical centers to be involved in a subsequent clinical trial completed an individual semi-structured interview. The verbatim transcripts were condensed independently by 2 researchers into a draft list of interventions. The researchers then resolved disagreement through discussion and produced a preliminary list of interventions. At a focus group meeting, the participating physiotherapists discussed the preliminary list, refined it to produce a final list, and then transformed it into a draft treatment schedule. The draft treatment schedule was piloted in clinical practice. Refinements were made, and the final treatment schedule was produced. RESULTS The treatment schedule consists of an A4 recording form with instructions and glossary of terms printed on the back. Each treatment record provides information including duration of treatment, treatment aims, and the 45 specific physical therapy interventions provided in the 11 sections (e.g., "splinting techniques" and "function - in sitting towards standing"). CONCLUSION A treatment schedule was produced, which can now be used in a subsequent phase II evaluative trial.
Collapse
Affiliation(s)
- V M Pomeroy
- Centre for Rehabilitation and Ageing, Geriatric Medicine, St George's University of London, London, UK.
| | | | | | | | | |
Collapse
|
24
|
Tepper JE, O'Connell M, Hollis D, Niedzwiecki D, Cooke E, Mayer RJ. Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114. J Clin Oncol 2003; 21:3623-8. [PMID: 14512393 DOI: 10.1200/jco.2003.03.018] [Citation(s) in RCA: 80] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
PURPOSE Intergroup Study 0114 was designed to study the effect of various chemotherapy regimens delivered after potentially curative surgical resection of T3, T4, and/or node-positive rectal cancer. A subset analysis was undertaken to investigate the prevalence and influence of salvage therapy among patients with recurrent disease. PATIENTS AND METHODS Adjuvant therapy consisted of two cycles of fluorouracil (FU)-based chemotherapy followed by pelvic irradiation with chemotherapy and two more cycles of chemotherapy after radiation therapy. A total of 1,792 patients were entered onto the study and 1,696 were assessable. After a median of 8.9 years of follow-up, 715 patients (42%) had disease recurrence, and an additional 10% died without evidence of disease. Five hundred patients with follow-up information available had a single organ or single site of first recurrence (73.5% of all recurrences). RESULTS A total of 171 patients (34% of those with a single organ or single site of recurrence) had a potentially curative resection of the metastatic or locally recurrent disease. Single-site first recurrences in the liver, lung, or pelvis occurred in 448 patients (90% of the single-site recurrences), with 159 (35%) of these undergoing surgical resection for attempted cure. Overall survival differed significantly between the resected and nonresected groups (P <.0001), with overall 5-year probabilities of.27 and.06, respectively. Controlling for worst performance status at the time of recurrence does not alter this relationship. Patients who underwent salvage surgery had significantly increased survival (P <.001) for each site. CONCLUSION Attempted surgical salvage of rectal cancer recurrence is performed commonly in the United States. The chance of a long-term cure with such intervention is approximately 27%.
Collapse
Affiliation(s)
- J E Tepper
- Department of Radiation Oncology, Campus Box No. 7512, University of North Carolina, Chapel Hill, NC 27599-7512, USA.
| | | | | | | | | | | |
Collapse
|
25
|
Siebens H, Weston H, Parry D, Cooke E, Knight R, Rosato E. The Patient Care Notebook: quality improvement on a rehabilitation unit. Jt Comm J Qual Improv 2001; 27:555-67. [PMID: 11593889 DOI: 10.1016/s1070-3241(01)27049-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
BACKGROUND Shortened lengths of stay in acute and rehabilitation hospitals, continuing financial pressures on all postacute care services, and increasing out-of-pocket health care costs for patients and families challenge rehabilitation hospitals' patient education and discharge planning processes. Spaulding Rehabilitation Hospital (Boston) introduced a patient care notebook in a 15-bed satellite unit and pilot tested its contribution to the patient education and discharge planning process. DEVELOPING THE NOTEBOOK: The three-ring binder notebook included sections on medical appointments and phone numbers, understanding illness and medical care, coping with illness, physical activities, recommendations for the home, and community resources, with both standard and patient-specific information. RESULTS Most of the patients and caregivers who received the notebooks found them to be helpful, and most staff indicated that the notebook improved the teaching process. Telephone calls to the unit after home discharges decreased form 28 calls for 11 discharges to 6 calls for 21 discharges after the notebook began to be used regularly. DISCUSSION Staff felt that the process of using the notebook helped focus attention on teaching during the entire course of a patient's hospitalization rather than just a day or two before discharge. The patient care notebook process is being introduced to the entire hospital and to all patients, regardless of discharge location and the patient's literacy or proficiency with English. CONCLUSION In using the notebook, the QI team, and the entire unit staff, learned about the complexities of QI, patient education, and discharge planning. The notebook process was implemented throughout the hospital a little more than a year after the completion of the pilot project.
Collapse
Affiliation(s)
- H Siebens
- Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital/Harvard Medical School, Boston, MA, USA.
| | | | | | | | | | | |
Collapse
|
26
|
Gaine WJ, Andrew SM, Chadwick P, Cooke E, Williamson JB. Late operative site pain with isola posterior instrumentation requiring implant removal: infection or metal reaction? Spine (Phila Pa 1976) 2001; 26:583-7. [PMID: 11242390 DOI: 10.1097/00007632-200103010-00027] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
OBJECTIVES To elucidate the cause of late operative site pain in six cases of scoliosis managed with Isola posterior instrumentation that required removal of the implants. METHOD Microbiologic examination of wound swabs and enriched culture of operative tissue specimens was undertaken in all cases. Histologic study of the peri-implant membranes also was conducted. RESULTS The presentation in all cases was similar: back pain appearing between 12-20 months after surgery, followed by a local wound swelling leading to a wound sinus. In only one of these cases was the discharge positive for bacterial growth. Implant removal was curative. Histologic examination of tissue specimens revealed a neutrophil-rich granulation tissue reaction suggestive of an infective etiology despite the failure to isolate organisms. Within the granulation tissue was metallic debris that varied from very sparse to abundant from fretting at the distal cross-connector junctions. A review of recent literature describing similar problems suggests that late onset spinal pain is a real entity and a major cause of implant removal. CONCLUSIONS On reviewing the evidence for an infective etiology versus a metallurgic reaction etiology for these cases of late onset spinal pain, it was concluded that a subacute low-grade implant infection was the main cause. Histologic findings would seem to confirm low-grade infection. There may be more than one causative factor for late operative site pain, as it is possible that fretting at cross connection junctions may provide the environment for the incubation of dormant or inactive microbes.
Collapse
Affiliation(s)
- W J Gaine
- Department of Orthopaedics, Royal Manchester Children's Hospital, Salford, UK
| | | | | | | | | |
Collapse
|
27
|
Norris C, Cooke E. Mental health training scheme for police officers. Prof Nurse 2000; 15:655-8. [PMID: 12026464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
A previous study found that 61% of police officers said they had not received sufficient training to deal with problems involving mentally ill people. Training in this area can help police officers acquire awareness and understanding in order to aid the management of people with mental health problems. Police feedback on the training was largely positive, emphasising the potential for nationwide training on such issues.
Collapse
Affiliation(s)
- C Norris
- Hutton Centre, St Luke's Hospital, Middlesborough
| | | |
Collapse
|
28
|
Abstract
Six cases of loss of flexor pollicis longus function after plating of a radius fracture are presented. The exact aetiology of the postoperative deficit is uncertain, but is probably a traction neuropraxia of the anterior interosseous nerve branches to the flexor pollicis longus. All six patients had full recovery within 5 months. An initial conservative approach is recommended if this complication is encountered.
Collapse
Affiliation(s)
- P Keogh
- Department of Orthopaedic Surgery, Tullamore Hospital, Republic of Ireland
| | | | | | | |
Collapse
|
29
|
Tepper JE, O'Connell MJ, Petroni GR, Hollis D, Cooke E, Benson AB, Cummings B, Gunderson LL, Macdonald JS, Martenson JA. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J Clin Oncol 1997; 15:2030-9. [PMID: 9164215 DOI: 10.1200/jco.1997.15.5.2030] [Citation(s) in RCA: 168] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
PURPOSE The combination of radiation therapy with fluorouracil (5-FU)-based chemotherapy is generally accepted as appropriate postoperative therapy for patients with adenocarcinomas of the rectum that extend through the bowel wall or with lymph nodes positive for tumor. We attempted to determine whether the efficacy of this postoperative therapy could be improved by the addition of leucovorin and/or levamisole. METHODS A total of 1,696 patients were randomized and eligible for treatment with one of four treatment schemes. All patients received two cycles of bolus 5-FU-based systemic chemotherapy followed by pelvic radiation therapy with chemotherapy and two more cycles of the same systemic chemotherapy. Chemotherapy was either 5-FU alone, 5-FU with leucovorin, 5-FU with levamisole, or 5-FU with leucovorin and levamisole. RESULTS With a median follow-up duration of 48 months, there is no statistically significant advantage to any of the treatment regimens compared with bolus 5-FU alone. There is evidence of increased gastrointestinal toxicity with the three-drug combination compared with bolus 5-FU alone. Statistical analysis suggests it is very unlikely that either levamisole-containing combination will be shown to be of value with further follow-up evaluation. CONCLUSION There is no evidence at present for a beneficial effect of levamisole in the adjuvant treatment of rectal cancer. Definitive evaluation of the effect of the addition of leucovorin to 5-FU and pelvic radiation will require further follow-up evaluation.
Collapse
Affiliation(s)
- J E Tepper
- Department of Radiation Oncology, University of North Carolina at Chapel Hill, School of Medicine 27599-7512, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Gorlin JB, Vamvakas EC, Cooke E, Galacki D, Geha R, Humphreys D, Kent P. Large-volume leukapheresis in pediatric patients: processing more blood diminishes the apparent magnitude of intra-apheresis recruitment. Transfusion 1996; 36:879-85. [PMID: 8863774 DOI: 10.1046/j.1537-2995.1996.361097017173.x] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
BACKGROUND Recruitment of progenitors during a large-volume collection, as defined by increasing relative and absolute numbers of progenitors (colony-forming units-granulocyte-macrophage [CFU-GM] of CD34+ cells), has been reported previously. STUDY DESIGN AND METHODS To ascertain whether intra-apheresis recruitment occurs in pediatric patients who have undergone mobilization with chemotherapy and granulocyte-colony-stimulating factor (G-CSF), each hour's portion of a 4-hour leukapheresis was collected into separate bags, and assessed by complete blood count, CFU-GM, and CD34+ cell assays. Seven pediatric patients (median age, 7; range, 2-19) were studied in connection with 2 to 4 collections each, for a total of 21 collections (with hourly samples). The collections lasted for 4 hours, at an inlet rate of 1 to 3 mL per kg per minute, for daily processing totals of 5 to 12 blood volumes. (One blood volume [mL] is estimated by the patient's weight in kg x 70 mL/kg.) Smaller (younger) patients had inlet rates exceeding 2 mL per kg per minute, and larger (older) patients had rates of 1 to 1.5 mL per kg per minute. CFU-GM and CD34+ cell counts obtained each hour of the collection and divided by the first hour's value were compared by nonparametric repeated-measures ANOVA. RESULTS Second-, third- and fourth-hour CD34+ progenitor cell counts were arithmetically higher than first-hour counts, but the trend did not reach significance (p = 0.1561). Second-hour counts were higher than first-hour counts in the overall analysis (mean +/- standard error [SE], 1.00 and 1.39 +/- 0.1, respectively; p = 0.0525) and in children older than 5 years (1.00 vs. 1.70 +/- 0.30, respectively; p = 0.0259), but not in children younger than 5 years (p = 0.8125). CFU-GM counts did not differ among the 4 hours of collection (p = 0.1717) or between the first and second hour (p = 0.9587). CONCLUSION In larger (older) patients, from whom fewer blood volumes were collected, there is a trend toward intra-apheresis recruitment, although less than reported previously. In the smaller (younger) patients, from whom more blood volumes were collected, no trend was observed. Lack of (or submaximal) prior mobilization in previously reported studies may have facilitated intracollection recruitment. Alternatively, the larger number of blood volumes collected from the smaller (younger) patients may have masked intra-apheresis recruitment. The study documents the feasibility of large-volume, 4-hour leukapheresis in pediatric patients.
Collapse
Affiliation(s)
- J B Gorlin
- Division of Laboratory Medicine, Children's Hospital, Boston, Massachusetts, USA
| | | | | | | | | | | | | |
Collapse
|
31
|
|
32
|
Cooke E. Dealing with the diabetic foot. Practitioner 1996; 240:112-4. [PMID: 8736199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
- E Cooke
- Clinical Microvascular Unit, St Bartholomews' Hospital Medical College, London
| |
Collapse
|
33
|
Cooke E. Reflex sympathetic dystrophy. Practitioner 1995; 239:521-3. [PMID: 7567772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- E Cooke
- Thermographic and Blood Flow Unit, St Bartholomew's Hospital Medical College, London
| |
Collapse
|
34
|
Cooke E. Current thinking on peripheral vascular disease. Practitioner 1995; 239:120-4. [PMID: 7708615] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- E Cooke
- St Bartholomew's Hospital, London
| |
Collapse
|
35
|
George J, Turner J, Cooke E, Hennessy E, Savage W, Julian P, Cochrane R. Women's knowledge of emergency contraception. Br J Gen Pract 1994; 44:451-4. [PMID: 7748633 PMCID: PMC1239018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
BACKGROUND More widespread use of emergency contraception could help to reduce the number of unwanted pregnancies. AIM The objective of this study was to assess women's knowledge of emergency contraception. METHOD A questionnaire was distributed to 1290 women aged between 16 and 50 years attending 14 general practice surgeries in London over a two-week period in 1990. RESULTS The response rate was 70%. Over three quarters of the women had heard of emergency contraception; these were mainly women who used contraception, who had higher educational qualifications or who were not Muslim. Women who were the most likely to need and to use emergency contraception--those using barrier methods--had no more accurate knowledge than women using any other method of contraception. Only 53% of barrier method users knew emergency contraception could be used as a backup when other methods failed. Only one fifth of women had heard about this method from their general practitioner or any other health professional, while half had obtained their information from the media. CONCLUSION These results suggest that including information on emergency contraception in consultations with users of barrier methods of contraception is a small step which general practitioners and practice nurses could take to increase the use of emergency contraception.
Collapse
Affiliation(s)
- J George
- Department of General Practice and Primary Care, Joint Medical College of St. Bartholomew's, London
| | | | | | | | | | | | | |
Collapse
|
36
|
Rosengren SS, Longobucco DB, Bernstein BA, Fishman S, Cooke E, Boctor F, Lewis SC. Meconium testing for cocaine metabolite: prevalence, perceptions, and pitfalls. Am J Obstet Gynecol 1993; 168:1449-56. [PMID: 8498426 DOI: 10.1016/s0002-9378(11)90780-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
OBJECTIVES We determined the prevalence of prenatal cocaine use in a racially mixed sample of urban and suburban mothers and correlated its use with maternal demographics and newborn measurements. STUDY DESIGN Meconium from 621 consecutive newborns delivered at two university-affiliated urban hospitals were assayed for benzoylecgonine. Maternal and infant characteristics were linked anonymously with the results. Statistical analysis included t test, Fisher's exact test, Duncan's multiple range analysis, and analysis of covariance, with a value of p < 0.05 considered significant. RESULTS We found that 3.4% of meconium samples had benzoylecgonine levels exceeding 0.1 micrograms/ml. Its presence was statistically correlated with maternal and neonatal characteristics. A nurse's opinion of cocaine use was correct 22% of the time. CONCLUSIONS Prenatal cocaine use was statistically associated with multiparity, multigravidity, late-onset and clinic-based prenatal care, public assistance, nonwhite race, and low academic achievement. A nurse's opinion was a poor predictor of maternal cocaine use. Cocaine-exposed infants were significantly smaller, and this correlated best with nonwhite background.
Collapse
Affiliation(s)
- S S Rosengren
- Department of Pediatrics, Saint Francis Hospital and Medical Center, Hartford, Connecticut
| | | | | | | | | | | | | |
Collapse
|
37
|
Williams G, Cardoso H, Ball JA, Mulderry PK, Cooke E, Bloom SR. Potent and comparable vasodilator actions of A- and B-calcitonin-gene-related peptides on the superficial subcutaneous vasculature of man. Clin Sci (Lond) 1988; 75:309-13. [PMID: 3262028 DOI: 10.1042/cs0750309] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
1. Vasoactivity of human A- and B-calcitonin-gene-related peptides was studied in normal subjects, using reflectance plethysmography to measure relative changes in blood flow produced by superficial subcutaneous injections of the peptides. 2. Injection of 10(-11) mol of either peptide caused an immediate 200% increase in local blood flow and prolonged hyperaemia lasting up to 3 h. The hyperaemic response to 10(-13) mol of each peptide was significantly (P less than 0.01) smaller and shorter in duration than that elicited by 10(-11) mol of the same peptide, and 10(-15) mol of both peptides produced no hyperaemia other than that attributable to needle insertion alone. 3. At all three dosages examined, there were no significant differences between A- and B-calcitonin-gene-related peptides in magnitude or time course of the hyperaemic response. 4. Human A- and B-calcitonin-gene-related peptides are therefore potent vasodilators in man, causing comparable dose-related vasodilatation in the superficial tissues.
Collapse
Affiliation(s)
- G Williams
- Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London
| | | | | | | | | | | |
Collapse
|
38
|
Cooke E, Al-Mohanna FA, Hallett MB. Diacylglycerol kinase inhibitor, R59022, potentiates neutrophil oxidase activation by Ca2+-dependent stimuli. Evidence for two separate but convergent pathways. Biochem Pharmacol 1987; 36:3459-62. [PMID: 2823820 DOI: 10.1016/0006-2952(87)90326-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
An inhibitor of diacylglycerol kinase, R59022, enhanced activation of the neutrophil oxidase stimulated by the Ca2+-ionophore, A23187 (1 microM), and by N-formyl-methionyl leucyl-phenylalanine (1 microM). The enhancement was reversed by two inhibitors of c-kinase, retinal (10 microM), and gossypol (20 microM). Activation by phorbol-myristyl-acetate and unopsonised latex beads were not enhanced. It was concluded that the chemotactic peptide generated diacylglycerol, but that maximum activation of c-kinase by this route was not achievable. The role of diacylglycerol in activation by beads remained unclear.
Collapse
Affiliation(s)
- E Cooke
- University Department of Surgery, University of Wales College of Medicine, Cardiff, U.K
| | | | | |
Collapse
|
39
|
Mondal B, Ganguli A, Cooke E. Keeping out the cold. Nurs Times 1987; 83:54-5. [PMID: 3684629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
40
|
Horgan K, Cooke E, Hallett MB, Mansel RE. Inhibition of protein kinase C mediated signal transduction by tamoxifen. Importance for antitumour activity. Biochem Pharmacol 1986; 35:4463-5. [PMID: 3790165 DOI: 10.1016/0006-2952(86)90764-1] [Citation(s) in RCA: 99] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Recent studies have demonstrated tamoxifen inhibition of the enzyme protein kinase C (PKC) in vitro. The aim of this study was to investigate the effects of tamoxifen on PKC function in intact human cells. As PKC activates the neutrophil oxidase mechanism the neutrophil was chosen as an experimental model to assess PKC-tamoxifen interaction in these experiments. Neutrophils from healthy volunteers were separated by centrifugation through Ficoll Hypaque. Two separate parameters of oxidase activation; oxygen consumption and reactive oxygen metabolite production were monitored by a Clark electrode chamber and luminol dependent chemiluminescence respectively. Neutrophil chemiluminescence was markedly stimulated by 4 Phorbol-12 myristate-13 acetate (PMA). This stimulation was inhibited by tamoxifen; IC50 = 6.1 +/- 1.6 microM (means +/- S.E.M.) N = 6. Neutrophil oxygen consumption was similarly stimulated by PMA and inhibited by tamoxifen. The tamoxifen inhibition was not due to cell toxicity as assessment of cell integrity by the exclusion of trypan blue and measurement of intracellular concentrations of ATP showed no significant differences before and after treatment. Tamoxifen also inhibited neutrophil chemiluminescence which was stimulated by oleoyl acetyl glycerol and mezerein excluding interaction with PMA as an explanation of its inhibitory effect. These results are consistent with tamoxifen inhibition of PKC function in intact human cells. This may be central to its antitumour action.
Collapse
|
41
|
Cooke E, Hallett MB. The role of C-kinase in the physiological activation of the neutrophil oxidase. Evidence from using pharmacological manipulation of C-kinase activity in intact cells. Biochem J 1985; 232:323-7. [PMID: 4091792 PMCID: PMC1152882 DOI: 10.1042/bj2320323] [Citation(s) in RCA: 72] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
The role of C-kinase in the triggering of the neutrophil oxidase by two stimuli (latex beads and the chemotactic peptide fMet-Leu-Phe), representative of endocytotic and exocytotic routes of activation, were investigated by using experimental agents that activate, or inhibit C-kinase, in intact cells. The activation by the phagocytotic stimulus latex beads was mimicked by C-kinase activators giving the same characteristic lag (20-30s), followed by a constant oxygen consumption rate with the same maximum rate and affinity for oxygen (Km approx. 13 microM), competed with activation by PMA (4 beta-phorbol 12-myristate 13-acetate) in a simple common-target manner, and was inhibited by retinal, an inhibitor shown to inhibit activation by PMA. In contrast, activation by chemotactic peptide was not mimicked by C-kinase activation alone, chemotactic peptide inducing biphasic oxygen consumption with a Km for oxygen of the second prolonged phase of 3.9 microM, did not compete with activation by PMA, and was not inhibited by retinal. However, PMA and retinal produced slight enhancements of activation by chemotactic peptide and production of monophasic oxygen consumption. It was concluded that C-kinase activation plays a simple central transducing role in activation of the oxidase by latex beads, but that its role in activation by chemotactic peptide is a part of a more complex set of interactions that involve other Ca2+-activated and non-Ca2+-activated processes.
Collapse
|
42
|
Cooke E. Holding on to the patient. Nurs Times 1984; 80:46-47. [PMID: 6568638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
|
43
|
Williams G, Pickup J, Clark A, Bowcock S, Cooke E, Keen H. Changes in blood flow close to subcutaneous insulin injection sites in stable and brittle diabetics. Diabetes 1983; 32:466-73. [PMID: 6341130 DOI: 10.2337/diab.32.5.466] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Photoelectric plethysmography (PPG) was used to investigate blood flow changes close to superficial subcutaneous injection sites. As a validation procedure, the PPG response to subcutaneous injection of a known hyperemic agent, prostaglandin E1 (10(-5) M), was shown to correlate strongly with subcutaneous blood flow changes estimated by the established technique of 133Xe washout. Changes in blood flow over the subcutaneous injection sites of insulin (Actrapid) and insulin diluent were measured by photoelectric plethysmography in six nondiabetics and in six stable and seven brittle insulin-dependent diabetics. In all subject groups, an acute increase in local blood flow was seen within 2 min of both insulin and diluent injections, probably caused by injection trauma. At diluent injection sites, this acute hyperemia faded rapidly, blood flow returning to preinjection levels within 15-20 min, and there was no further increase in blood flow in any of the subjects. Insulin injected into the nondiabetics and stable diabetics caused a pronounced increase in local blood flow, sustained for at least 60 min after injection. In the brittle diabetics, however, there was no prolonged local hyperemia, the response being significantly less than that seen in both the nondiabetics and the stable diabetics. Insulin-related hyperemia close to injection (or infusion) sites may be important in subcutaneous insulin absorption. Its near-absence in brittle diabetics may contribute to the impaired response to subcutaneous insulin characteristic of these patients.
Collapse
|
44
|
Williams G, Pickup JC, Bowcock S, Cooke E, Keen H. Subcutaneous aprotinin causes local hyperaemia. A possible mechanism by which aprotinin improves control in some diabetic patients. Diabetologia 1983; 24:91-4. [PMID: 6188643 DOI: 10.1007/bf00297388] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Local changes in blood flow at the subcutaneous injection site of the proteinase inhibitor aprotinin and its diluent were measured by photoelectric plethysmography. Aprotinin, but not its diluent, caused local hyperaemia in five normal subjects and in five stable and five brittle insulin-dependent diabetic patients, local blood flow increasing by 80%-180%. The duration of the hyperaemic response was shorter in the brittle diabetic patients than in the other two groups, but there was wide individual variation. Aprotinin is known to enhance subcutaneous insulin absorption in normal subjects and in some brittle diabetic patients. The basis for this might be through increasing blood flow near the injection site rather than by inhibition of insulin breakdown.
Collapse
|
45
|
Cooke E. Off-air copying update: guidelines, advice to educators. Am Libr 1981; 12:663-4. [PMID: 10253696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
46
|
Abstract
Electrodermal activity was measured bilaterally at rest and during stimulation in 22 schizophrenic, 11 depressed and 12 anxiety state patients, and in 32 normal volunteers. No group showed a distinctive pattern of lateral asymmetry. The frequency of spontaneous fluctuation in electrodermal activity was greater in the anxiety state and schizophrenic groups and in those patients who reported auditory hallucination during recording. Few schizophrenic subjects failed to respond to visual stimulation but substantial minority failed to habituate. The implications of these findings are discussed.
Collapse
|
47
|
Chattopadhyay P, Cooke E, Toone B, Lader M. Habituation of physiological responses in anxiety. Biol Psychiatry 1980; 15:711-21. [PMID: 7417628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
In the first study, 20 male and 20 female volunteers were studied under threat-of-shock and no-threat conditions with respect to anxiety levels, skin conductance, EEG auditory evoked response, and alpha-blocking variables. The threat-of-shock increased anxiety levels, skin conductance level, and fluctuations. The P300 component of the AER was greater in anxious individuals and habituation of the alpha-blocking response was retarded. In the second study, 12 anxious patients were compared with 12 normal subjects under threat-of-shock and 12 normal subjects under no-threat. Anxiety was associated with increased skin conductance fluctuations, larger P300 AER components, and impaired habituation of the alpha response.
Collapse
|
48
|
Toone BK, Cooke E, Lader MH. The effect of temporal lobe surgery on electrodermal activity: implications for an organic hypothesis in the aetiology of schizophrenia. Psychol Med 1979; 9:281-285. [PMID: 472073 DOI: 10.1017/s0033291700030774] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
It has recently been suggested that the bilateral asymmetry of electrodermal activity (EDA) reported in schizophrenia may be related to unilateral temporal lobe dysfunction. To test this hypothesis, 3 aspects of EDA--skin conductance level (SCL), number of spontaneous fluctuations (SF), and skin conductance response (SCR)--were measured bilaterally in 10 patients who had undergone unilateral temporal lobectomy. No differences could be detected between the operated and non-operated sides within the patient group, nor between the patient and control groups. The implications of these findings are discussed.
Collapse
|
49
|
Abstract
Ninety-seven one-hour recordings of the abdominal fetal electrocardiogram (ECG) were made from 59 normal patients between 21 and 41 weeks of gestation. The heart intervals, measured between successive R-waves, were analysed by computer. The signal-to-noise ratio of the fetal ECG limited the precision of the interval measurements to approximately one millisecond. The characteristics of the baseline heart rate changed significantly as gestation advanced, the mean R-R interval, the standard deviation of the intervals and the standard deviation of the interval differences all increasing with gestation (p less than 0.001). In later gestation the baseline heart rate during periods of fetal rest differed significantly from that during periods of fetal activity; during rest the mean R-R interval was greater (p smaller than 0.001) and the standard deviations of the intervals and interval differences were smaller (p smaller than 0.001). Examination of the coefficient of variation of the heart intervals gave a result which contradicted the significance of this measurement as an index of fetal welfare as proposed by Curran and MacGregor (1970).
Collapse
|
50
|
Gordon YB, Chard T, Cooke E. Deep vein thrombosis in pregnancy. West J Med 1976. [DOI: 10.1136/bmj.1.6001.97-a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|